转自：新华财经 寒武纪8月14日晚间的股价异动公告称，公司股票交易连续三个交易日内（2025年8月12日、8月13日、8 月14日）收盘价格涨幅偏离值累计达到30%，股价短期涨幅较大。最近一个月，公司股价累计涨幅超过 大部分同行业公司股价涨幅且显著高于科创综指、科创50、上证综指等相关指数涨幅，公司股价持续上 涨积累了较多的获利调整风险。特别提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 截至8月14日，公司收盘价为949.00元／股。根据中证指数有限公司发布的数据，公司最新滚动市盈率 为3058.57，市净率为68.12倍。而公司所处的软件和信息技术服务业最新滚动市盈率为75.15，市净率为 5.07倍，公司滚动市盈率、市净率显著高于行业水平。 公司自查，并向公司控股股东、实际控制人发函 查证，截至公告披露日，确认不存在关于公司的应披露而未披露的重大事项。公司目前经营正常，未发 生重大变化。 编辑：王媛媛 公告称，公司近期关注到网上传播的关于公司在某厂商预定大量载板订单、收入预测、新产品情况、送 样及潜在客户、供应链等相关信息，均为误导市场的不实信息。请投资者理性决策，注意投资风险。 寒武纪近几日 ...

Core Viewpoint - Company refutes recent market rumors regarding large orders and revenue forecasts, urging investors to make rational decisions [2][3] Group 1: Company Response - On August 14, the company issued a statement addressing market rumors about significant orders and financial forecasts, labeling them as misleading information [2] - The company confirmed that it has not disclosed any major undisclosed matters and that its operations are normal [3] Group 2: Stock Performance - Following rumors on August 12, the company's stock surged, hitting a daily limit increase of 20%, and closed at a record high of 949.00 CNY per share on August 14 [2][3] - The stock has seen a cumulative increase over the past month that outpaces most peers in the industry and major indices [3] Group 3: Financial Metrics - As of August 14, the company's rolling price-to-earnings (P/E) ratio was 3058.57, and the price-to-book (P/B) ratio was 68.12, significantly higher than the industry averages of 75.15 and 5.07, respectively [3]

Core Viewpoint - The company, Cambrian (688256), has issued a statement to refute recent market rumors regarding significant orders and revenue forecasts, urging investors to make rational decisions and be cautious of investment risks [2][5]. Group 1: Rumors and Market Reactions - On August 12, market rumors suggested that Cambrian had increased its procurement of substrates and wafers, leading to a significant stock price surge, with a "20cm" limit up on that day [2]. - Following the rumors, Cambrian's stock price experienced a small increase of 1.31% on August 13, and on August 14, it surged again, reaching a peak of 985 CNY per share, just shy of the 1000 CNY mark [3][5]. Group 2: Financial Metrics and Comparisons - As of August 14, Cambrian's stock price closed at 949.00 CNY per share, with a rolling price-to-earnings (P/E) ratio of 3058.57 and a price-to-book (P/B) ratio of 68.12, significantly higher than the industry averages of 75.15 for P/E and 5.07 for P/B [5]. - The company noted that its stock price had increased more than that of most peers in the industry and was significantly above the growth rates of relevant indices such as the Sci-Tech Innovation Board Composite Index and the Shanghai Composite Index [5].

8月14日，A股市场再度迎来投资风险提示。长城军工连续10个交易日内股价涨幅偏离值累计超过100%，公司发布严重异常波动公告。该股自7月31日至8月 13日期间表现异常活跃，引发监管层关注。与此同时，多家上市公司也相继发布风险提示公告，提醒投资者理性参与交易。 作者：观察君 多家公司集中发布投资风险警示 除长城军工外，吉视传媒也在同期发布异动公告。该公司股票在8月7日至8月13日期间连续5个交易日涨停，累计涨幅较大。公司澄清称，经自查不涉及"国 资云"相关业务，也不参与投资目前上映的影片。 针对投资者关注的电影《731》投资情况，吉视传媒表示公司出资比例极低。该投资预计对公司业绩几乎不构成重大影响，后续进展存在不确定性。这一澄 清旨在纠正市场对公司业务范围的误解。 创新医疗同样发布风险提示，该公司连续三个交易日收盘价格涨幅偏离值累计超过20%。公司持有博灵脑机40%股权，但强调博灵脑机产品尚未正式上市， 仅因与科研机构合作而销售少量产品。2023年和2024年，博灵脑机分别亏损660.17万元和866.41万元。 华康洁净则因董事长被采取留置措施发布公告。公司收到控股股东、实际控制人、董事长谭平涛家属通知，谭 ...

Core Viewpoint - Jihua Group has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, while the company continues to operate normally during the investigation period [3]. Group 1: Regulatory Issues - On August 8, 2025, Jihua Group received a notice of investigation from the CSRC due to suspected information disclosure violations [3]. - The company had previously been criticized by the Shanghai Stock Exchange in November 2024 for failing to disclose relevant borrowing matters in a timely manner [5]. - The company did not resolve borrowing issues before the equity transfer and failed to disclose related transactions involving its controlling shareholder [7]. Group 2: Financial Performance - Jihua Group's revenue has been declining, dropping from 15.436 billion yuan in 2022 to 9.886 billion yuan in 2024 [9]. - The company reported a significant net loss of 4.228 billion yuan in 2024, a year-on-year decrease of 2418.90% [9]. - The losses were attributed to impairment provisions for ineffective assets, inventory losses due to market changes, and devaluation of collateral assets [9]. Group 3: Stock Performance - Despite the financial struggles, Jihua Group's stock price has surged, reaching a limit-up price of 5.28 yuan per share on August 8, with a total market capitalization of 23.19 billion yuan [10]. - The stock price increased by 106.64% from a low of 2.39 yuan per share in April 2025 [10]. - The company has not engaged in brain-computer interface-related fields, which was mentioned in response to the stock price surge [10].

Core Viewpoint - The stock price of Upwind New Materials has significantly deviated from its fundamentals, prompting the company to resume trading on August 5 after a suspension due to abnormal trading activities [2][7]. Group 1: Stock Performance and Trading Activity - Upwind New Materials became the first tenfold stock in A-shares this year, with a cumulative stock price increase of over 10 times from July 9 to July 30 [5]. - During the abnormal trading period, the stock price increased by 1083.42%, significantly outpacing related indices such as the Sci-Tech Innovation Index and the Shanghai Composite Index [15]. - The stock's trading turnover rate was notably higher than previous levels, averaging 6.37% and reaching a median of 5.60% from July 22 to July 30 [15]. Group 2: Financial Performance and Future Outlook - The company expects a decline in performance for the first half of 2025, projecting revenue of 784 million yuan, a year-on-year increase of 12.50%, but a net profit decrease of 32.91% to approximately 29.9 million yuan [9][13]. - The anticipated decline in net profit is attributed to increased overseas sales shipping costs, exchange losses, and higher testing fees for recyclable products [13]. Group 3: Ownership and Control Changes - The controlling shareholder of Upwind New Materials will change to Shanghai Zhiyuan Hengyue Technology Partnership, with the actual controller being Deng Taihua [13]. - The company has stated that there are no plans for asset restructuring or significant changes in business operations in the next 12 months [13]. Group 4: Market Valuation - Upwind New Materials has a significantly high price-to-earnings (P/E) ratio of 418.77, compared to the industry average of 24.87 [15]. - The external float of the company's shares is relatively small, with major shareholders holding 85% of the total shares, leaving only about 15% for external circulation [16].

Core Viewpoint - The stock of Saiteng Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative price increase of 20% over three consecutive trading days from July 31 to August 4, 2025 [1] Group 1: Stock Performance - The stock price deviation was noted as an abnormal fluctuation, with a cumulative increase of 20% over the specified trading days [1] - The company disclosed that the abnormal trading was linked to a share reduction plan announced on May 9, 2025, which had not been fully executed by the announcement date [1] Group 2: Shareholding Changes - During the period of abnormal trading, shareholder Sun Feng executed a reduction of shares through block trading, consistent with the previously disclosed reduction plan [1] - There were no instances of other directors, supervisors, or senior management, including Ms. Zeng Hui, buying or selling company shares during the abnormal trading period [1]

Core Viewpoint - Yong'an Pharmaceutical (002365) has experienced significant stock price fluctuations, with a cumulative deviation exceeding 20% over two trading days, despite the company indicating no major changes in its fundamentals and warning of high speculation risks [1][2]. Financial Performance - Yong'an Pharmaceutical has faced declining revenues for three consecutive years, with reported revenues of 1.462 billion yuan, 973 million yuan, and 839 million yuan for 2022, 2023, and 2024 respectively, reflecting year-on-year declines of 6.58%, 33.48%, and 13.78% [2]. - The core business of taurine generated 635 million yuan in revenue for 2024, accounting for 75.67% of total revenue, but saw a year-on-year decline of 4.14% despite a 16.32% increase in sales volume due to falling prices [2]. - The company incurred a total loss of 17.588 million yuan from the shutdown of its ethylene oxide facility and Qi'an Hydrogen Energy, which accounted for 28.47% of net profit attributable to shareholders [2]. Management and Governance - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has been placed under investigation and detention, raising concerns about management stability [3]. - Despite the investigation, the company asserts that other board members and senior management are performing their duties normally, and that there has been no change in control or significant impact on daily operations [3]. Future Outlook - Yong'an Pharmaceutical faces multiple challenges, including ongoing performance pressures, obstacles in core business operations, setbacks in new business development, and management changes, raising questions about its future strategies [4].

Core Viewpoint - *ST Yazhen (SH603389) announced a stock suspension for verification starting June 12, 2025, following significant stock price fluctuations since May 2025, which raised concerns about potential risks of a price drop after a substantial increase [1][4]. Group 1: Stock Performance and Ownership Changes - Since May 2025, *ST Yazhen's stock price surged, with multiple instances of abnormal trading fluctuations [1]. - Wu Tao, a mining capital figure, acquired approximately 30% of *ST Yazhen's shares at a price of 5.68 yuan per share, resulting in a floating profit of about 128% as of June 11, 2025, amounting to over 500 million yuan in just seven trading days [3][6]. - The stock price increased from a low of 4.45 yuan on April 8, 2025, to 6.94 yuan by April 17, 2025, marking a rise of approximately 56% [6]. Group 2: Financial Performance and Risks - *ST Yazhen reported a negative net profit for the fiscal year 2024, with revenues excluding non-recurring items falling below 300 million yuan, leading to a delisting risk warning since May 6, 2025 [4]. - The company has experienced four consecutive years of losses, with a net loss exceeding 20 million yuan in the first quarter of 2025 [4]. - The company emphasized the need for investors to be aware of potential risks associated with the stock's short-term price fluctuations [4]. Group 3: Strategic Initiatives - In response to market challenges, *ST Yazhen aims to expand its market share in the mid-to-low-end product lines while leveraging existing industry resources for growth [5]. - The company has not identified any significant events or media reports that could have impacted its stock price, asserting that previous disclosures remain accurate [5].

这些年我在股市里摸爬滚打，也算总结出了一些关于换手率的经验，今天就跟大家掏心窝子分享分享，保管能让你少踩80%的坑。 1、低位横盘换手低。去年我就发现了一只股票，在历史底部晃悠了整整三个月，换手率一直都在3%以下。这时候就得留个心眼了，这很可能是庄家在悄悄 吃筹码。庄家就像个老谋深算的猎人，在低位慢慢收集筹码，等时机一到，就会拉升股价，咱要是能提前察觉，说不定就能跟着喝口汤。 各位股友们！今天咱就敞开了聊聊股市里换手率这点事儿。想当年我刚一脚踏进股市，那真叫一个懵圈，看到"换手率"这三个字，脑袋里就像一团乱麻，完 全摸不着头脑。 就说十年前吧，我刚入市没多久，有只重仓股连续三天换手率都超过了25%。我当时那个傻呀，满心期待着主力赶紧拉升，觉得这肯定是要大涨的节奏。结 果现实给了我狠狠一巴掌，账户里的钱直接亏掉了我两个月的工资。现在回想起来，要是当初能早点弄明白换手率的门道，哪至于走这么多弯路，交这么多 学费！ 2、高换手率可不一定都是好事。我就在这方面吃过大亏。有一次，我看到一只热门股换手率一下子冲到了30%，当时各路分析师都在喊"空中加油"，说得 那叫一个天花乱坠，我也跟着心动了。结果第二天，这股票直接高台 ...